Lexaria Reports $0 Revenue, Going Concern Warning, and Nasdaq Delisting Risk
LEXX sits 29% above its 52-week low of $0.46.
Summary
Lexaria's 10-Q reveals zero revenue for the quarter, down from $174K a year ago, as the company pivots from B2B clients to pharma partnerships. Net loss narrowed to $1.99M from $3.79M, but the filing includes a going concern warning and Nasdaq delisting risk with cash only into early 2027. The company raised $6.5M in registered offerings to fund trials, and completed a Phase 1b GLP-1 study showing favorable safety versus Rybelsus. FDA clearance for an IND-based hypertension program provides a potential pipeline catalyst, but survival hinges on near-term financing.
At the time of this announcement, LEXX was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.7M. The 52-week trading range was $0.46 to $1.55. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.